Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients

Transplant Infectious Disease

Volumn 11, Issue 2, 2009, Pages 106-111

  Brady, R L ^a   Green, K ^a   Frei, C ^b   Maxwell, Pamela ^a  

^a UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Liver transplant; Prophylaxis; Valganciclovir

Indexed keywords

GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TEXAS; TREATMENT OUTCOME;

EID: 64249105728     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2008.00356.x     Document Type: Article

References (19)

1. Slifkin M, Doron S, Snydman D. Viral prophylaxis in organ transplant patients. Drugs 2004 64 (24) : 2763 2792.
2. Singh N, Wannstedt C, Keyes L, et al. Who among cytomegalovirus- seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005 11 (6) : 700 704.
3. Paya CV, Razonable RR. Cytomegalovirus Infection After Solid Organ Transplantation. Chapter 20. Transplant Infections (2nd edn). Philadelphia : Lippincott Williams and Wilkins, 2003 : 298.
4. Rowshani A, Bemelman F, Leeuwen E, et al. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005 79 (4) : 381 386.
5. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006 82 (2S) : S4 S8.
6. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti-Infect Ther 2004 2 (1) : 27 41.
7. Cytomegalovirus. Am J Transplant 2004 4 (Suppl 10) : 51 58.
8. Das A. Cytomegalovirus infection in solid organ transplantation. Pharmacoeconomics 2003 21 (7) : 467 475.
9. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001 3 (Suppl 2) : 1 5.
10. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006 16 (5) : 289 295.
11. Freeman RB, Paya C, Pescovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Clin Transplant 2004 78 (12) : 1765 1771.
12. Hoppe L, Marroni CA, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplant Proc 2006 38 : 1922 1923.
13. ® Drug Point, Micromedex on-line. Thomson MICROMEDEX; accessed August 2007.
14. Valcyte (valganciclovir) Package Insert. Roche Pharmaceuticals, January 2006.
15. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4 : 611 620.
16. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 44 (10) : 2811 2815.
17. Jain A, Orloff M, Kashyap R, et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2006 37 : 3182 3186.
18. Park JM, Lake KD, Arenas JD, et al. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006 12 : 112 116.
19. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005 44 (5) : 495 507.